Andreas D Kistler

Summary

Affiliation: University Hospital
Country: Switzerland

Publications

  1. pmc Urinary proteomic biomarkers for diagnosis and risk stratification of autosomal dominant polycystic kidney disease: a multicentric study
    Andreas D Kistler
    Division of Nephrology, University Hospital, Zurich, Switzerland
    PLoS ONE 8:e53016. 2013
  2. doi request reprint Identification of a unique urinary biomarker profile in patients with autosomal dominant polycystic kidney disease
    Andreas D Kistler
    Department of Nephrology, University Hospital, Zurich, Switzerland
    Kidney Int 76:89-96. 2009
  3. doi request reprint Sirolimus and kidney growth in autosomal dominant polycystic kidney disease
    Andreas L Serra
    Division of Nephrology, University Hospital and the University of Zurich, Zurich, Switzerland
    N Engl J Med 363:820-9. 2010
  4. doi request reprint Safety and tolerability of sirolimus treatment in patients with autosomal dominant polycystic kidney disease
    Andreas L Serra
    Division of Nephrology, University Hospital Zurich, Institute of Physiology, Switzerland
    Nephrol Dial Transplant 24:3334-42. 2009
  5. pmc Soluble klotho and autosomal dominant polycystic kidney disease
    Ivana Pavik
    Institute of Physiology and Zurich Center for Integrative Human Physiology, Zurich, Switzerland
    Clin J Am Soc Nephrol 7:248-57. 2012
  6. doi request reprint Increases in kidney volume in autosomal dominant polycystic kidney disease can be detected within 6 months
    Andreas D Kistler
    Clinic for Nephrology, University Hospital, Zurich, Switzerland
    Kidney Int 75:235-41. 2009
  7. doi request reprint Kidney function and volume progression in unilateral autosomal dominant polycystic kidney disease with contralateral renal agenesis or hypoplasia: a case series
    Diane Poster
    Division of Nephrology, University Hospital, Zurich, Switzerland
    Am J Kidney Dis 54:450-8. 2009
  8. doi request reprint Patients with autosomal dominant polycystic kidney disease have elevated fibroblast growth factor 23 levels and a renal leak of phosphate
    Ivana Pavik
    Institute of Physiology and Zurich Center for Integrative Human Physiology, University of Zurich, Zurich, Switzerland
    Kidney Int 79:234-40. 2011
  9. pmc Low-dose oral sirolimus and the risk of menstrual-cycle disturbances and ovarian cysts: analysis of the randomized controlled SUISSE ADPKD trial
    Matthias Braun
    Division of Nephrology, University Hospital, Zurich, Switzerland
    PLoS ONE 7:e45868. 2012
  10. doi request reprint Autosomal dominant polycystic kidney disease: new treatment options and how to test their efficacy
    Rudolf P Wuthrich
    Division of Nephrology, University Hospital, Zurich, Switzerland
    Kidney Blood Press Res 32:380-7. 2009

Collaborators

Detail Information

Publications12

  1. pmc Urinary proteomic biomarkers for diagnosis and risk stratification of autosomal dominant polycystic kidney disease: a multicentric study
    Andreas D Kistler
    Division of Nephrology, University Hospital, Zurich, Switzerland
    PLoS ONE 8:e53016. 2013
    ..In conclusion, the performance of peptidomic biomarker scores is superior to any other biochemical markers of ADPKD and the proteomic biomarker patterns are a promising tool for prognostic evaluation of ADPKD...
  2. doi request reprint Identification of a unique urinary biomarker profile in patients with autosomal dominant polycystic kidney disease
    Andreas D Kistler
    Department of Nephrology, University Hospital, Zurich, Switzerland
    Kidney Int 76:89-96. 2009
    ..These findings present a potential hypothesis for the mechanisms of disease progression in ADPKD which will need to be confirmed by further studies...
  3. doi request reprint Sirolimus and kidney growth in autosomal dominant polycystic kidney disease
    Andreas L Serra
    Division of Nephrology, University Hospital and the University of Zurich, Zurich, Switzerland
    N Engl J Med 363:820-9. 2010
    ..In autosomal dominant polycystic kidney disease (ADPKD), aberrant activation of the mammalian target of rapamycin (mTOR) pathway is associated with progressive kidney enlargement. The drug sirolimus suppresses mTOR signaling...
  4. doi request reprint Safety and tolerability of sirolimus treatment in patients with autosomal dominant polycystic kidney disease
    Andreas L Serra
    Division of Nephrology, University Hospital Zurich, Institute of Physiology, Switzerland
    Nephrol Dial Transplant 24:3334-42. 2009
    ..Here we report the preliminary safety results of the first 6 months of treatment...
  5. pmc Soluble klotho and autosomal dominant polycystic kidney disease
    Ivana Pavik
    Institute of Physiology and Zurich Center for Integrative Human Physiology, Zurich, Switzerland
    Clin J Am Soc Nephrol 7:248-57. 2012
    ..This study explored potential mechanisms underlying resistance to FGF23 in ADPKD...
  6. doi request reprint Increases in kidney volume in autosomal dominant polycystic kidney disease can be detected within 6 months
    Andreas D Kistler
    Clinic for Nephrology, University Hospital, Zurich, Switzerland
    Kidney Int 75:235-41. 2009
    ..Our study shows that increases in kidney volume can be reliably measured over a 6 month period in early autosomal dominant polycystic kidney disease using unenhanced magnetic resonance imaging sequences...
  7. doi request reprint Kidney function and volume progression in unilateral autosomal dominant polycystic kidney disease with contralateral renal agenesis or hypoplasia: a case series
    Diane Poster
    Division of Nephrology, University Hospital, Zurich, Switzerland
    Am J Kidney Dis 54:450-8. 2009
    ..Whether unilateral ADPKD is associated with faster disease progression is not known...
  8. doi request reprint Patients with autosomal dominant polycystic kidney disease have elevated fibroblast growth factor 23 levels and a renal leak of phosphate
    Ivana Pavik
    Institute of Physiology and Zurich Center for Integrative Human Physiology, University of Zurich, Zurich, Switzerland
    Kidney Int 79:234-40. 2011
    ..The mechanism for this anomaly will require further study...
  9. pmc Low-dose oral sirolimus and the risk of menstrual-cycle disturbances and ovarian cysts: analysis of the randomized controlled SUISSE ADPKD trial
    Matthias Braun
    Division of Nephrology, University Hospital, Zurich, Switzerland
    PLoS ONE 7:e45868. 2012
    ....
  10. doi request reprint Autosomal dominant polycystic kidney disease: new treatment options and how to test their efficacy
    Rudolf P Wuthrich
    Division of Nephrology, University Hospital, Zurich, Switzerland
    Kidney Blood Press Res 32:380-7. 2009
    ..The present review will discuss the utility and the techniques for kidney and cyst volume measurements to assess disease progression in ADPKD, and summarizes ongoing clinical trials testing novel therapeutic options...
  11. pmc A distinct urinary biomarker pattern characteristic of female Fabry patients that mirrors response to enzyme replacement therapy
    Andreas D Kistler
    Division of Nephrology, University Hospital, Zurich, Switzerland
    PLoS ONE 6:e20534. 2011
    ..In conclusion, we defined a urinary biomarker model that seems to be of diagnostic use for Fabry disease in female patients and may be used to monitor response to enzyme replacement therapy...
  12. pmc Clinical proof-of-concept trial to assess the therapeutic effect of sirolimus in patients with autosomal dominant polycystic kidney disease: SUISSE ADPKD study
    Andreas L Serra
    Clinic for Nephrology, University Hospital, CH 8091 Zurich, Switzerland
    BMC Nephrol 8:13. 2007
    ..Based on these promising results in animals we have designed and initiated the first randomized controlled trial (RCT) to examine the effectiveness, safety and tolerability of sirolimus to retard disease progression in ADPKD...